AEterna Zentaris announces positive peliminary results for Phase 2 study with LHRH-receptor targeted cytotoxic conjugate AEZS-108 in ovarian cancer (AEZS) 1.02 : Co announces positive efficacy data from a Phase 2 study with its targeted cytotoxic peptide conjugate, AEZS-108, in patients with platinum-resistant and taxane-pretreated ovarian cancer. In a personalized healthcare approach, the study selected patients with tumors expressing LHRH receptors, the key element in the targeting mechanism of AEZS-108. Under coordination by Prof. Gunter Emons, MD, Chairman of the Department of Obstetrics & Gynaecology at the University of Gottingen, Germany, this open-label, multi-center and multi-national Phase 2 study 'AGO-GYN-5' is being conducted by the German AGO Study Group, in cooperation with clinical sites in Europe. All 43 patients with LHRH-receptor positive ovarian cancer who entered study AGO-GYN-5 have completed their study treatment. A preliminary evaluation shows that the study met its primary efficacy endpoint of 5 or more responders in 41 evaluable patients. Responders, as well as patients with stable disease after completion of treatment with AEZS-108, will now be followed to assess the duration of progression-free survival and, ultimately, overall survival